Physician profile
Melissa A Ramirez
NPI 1750610184
$9,355.76
in general payments reported to CMS, 2019-2025
32 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 92% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $378 · 2021: $1,091 · 2022: $1,539 · 2023: $1,656 · 2024: $1,897 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,175.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,356.16 | 2021-2025 | |
| Corium, LLC | $885.03 | 2021-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $876.76 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $850.41 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $653.47 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $648.90 | 2019-2025 | Spravato, Invega |
| Ironshore Pharmaceuticals INC. | $543.80 | 2019-2024 | Jornay Pm |
| Alkermes, INC. | $479.34 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $328.85 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $313.44 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $310.65 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $308.66 | 2022-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $275.20 | 2019-2025 | Dyanavel Xr |
| Neos Therapeutics, Lp | $249.17 | 2019-2023 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $186.98 | 2020-2025 | Ingrezza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $156.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $139.78 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vertical Pharmaceuticals, LLC | $128.57 | 2024-2025 | Relexxii |
| Bausch Health US, LLC | $102.07 | 2019-2025 | Aplenzin |
| Almatica Pharma LLC | $97.22 | 2021-2023 | Loreev Xr |
| Adlon Therapeutics L.P. | $96.26 | 2020-2021 | |
| Axsome Therapeutics, INC. | $93.81 | 2023-2024 | Auvelity |
| Shire North American Group INC | $41.23 | 2019 | |
| Harmony Biosciences LLC | $39.38 | 2025 | |
| Collegium Pharmaceutical, INC. | $36.68 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $34.78 | 2023 | Belsomra |
| Noven Therapeutics, LLC | $29.26 | 2024 | Xelstrym, Secuado |
| Eisai INC. | $25.32 | 2021 | |
| Portola Pharmaceuticals, LLC | $24.14 | 2019 | |
| Alfasigma USA, INC. | $18.49 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.02 | 2023 | Quviviq |
| Neuronetics, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.